Cargando…

Advanced glycation end products as a source of artifacts in immunoenzymatic methods

The most abundant proteins in the arteries are those of extracellular matrix, ie. collagen and elastin. Due to their long half-lifes these proteins have an increased chance to undergo glycation. The aim of this study was to determine relationship between the content of the main extracellular matrix...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuzan, Aleksandra, Chwiłkowska, A., Maksymowicz, K., Bronowicka-Szydełko, A., Stach, K., Pezowicz, C., Gamian, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5849676/
https://www.ncbi.nlm.nih.gov/pubmed/29305778
http://dx.doi.org/10.1007/s10719-017-9805-4
_version_ 1783306078915657728
author Kuzan, Aleksandra
Chwiłkowska, A.
Maksymowicz, K.
Bronowicka-Szydełko, A.
Stach, K.
Pezowicz, C.
Gamian, A.
author_facet Kuzan, Aleksandra
Chwiłkowska, A.
Maksymowicz, K.
Bronowicka-Szydełko, A.
Stach, K.
Pezowicz, C.
Gamian, A.
author_sort Kuzan, Aleksandra
collection PubMed
description The most abundant proteins in the arteries are those of extracellular matrix, ie. collagen and elastin. Due to their long half-lifes these proteins have an increased chance to undergo glycation. The aim of this study was to determine relationship between the content of the main extracellular matrix proteins and the advanced glycation end products (AGEs) in arteries. In this study 103 fragments of aorta were analyzed by ELISA and immunobloting for the content of collagens type I, III and IV and elastin and the content of advanced glycation end-products (AGE). A negative correlation between the content of collagens type III and IV and AGE (r = −0,258, p = 0,0122, and a weak negative correlation between collagen type III and age of the sample donor (r = 0,218, p = 0,0262) were demonstrated. This result comes as a surprise and it contradicts an intuitive assumption that with more glycation substrate, i.e. matrix proteins, more AGE products are expected. We have concluded that the results of the ELISA tests must have been influenced by the glycation. As a consequence, either modified protein molecules were not being recognized by the antibodies, or the glycation, and formation of crosslinks have blocked access of the antibodies to the antigen. It will conceal the effect of the linear dependence between the result (absorbance/densitometry) from the quantity of protein to which the antibody is directed.
format Online
Article
Text
id pubmed-5849676
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-58496762018-03-21 Advanced glycation end products as a source of artifacts in immunoenzymatic methods Kuzan, Aleksandra Chwiłkowska, A. Maksymowicz, K. Bronowicka-Szydełko, A. Stach, K. Pezowicz, C. Gamian, A. Glycoconj J Original Article The most abundant proteins in the arteries are those of extracellular matrix, ie. collagen and elastin. Due to their long half-lifes these proteins have an increased chance to undergo glycation. The aim of this study was to determine relationship between the content of the main extracellular matrix proteins and the advanced glycation end products (AGEs) in arteries. In this study 103 fragments of aorta were analyzed by ELISA and immunobloting for the content of collagens type I, III and IV and elastin and the content of advanced glycation end-products (AGE). A negative correlation between the content of collagens type III and IV and AGE (r = −0,258, p = 0,0122, and a weak negative correlation between collagen type III and age of the sample donor (r = 0,218, p = 0,0262) were demonstrated. This result comes as a surprise and it contradicts an intuitive assumption that with more glycation substrate, i.e. matrix proteins, more AGE products are expected. We have concluded that the results of the ELISA tests must have been influenced by the glycation. As a consequence, either modified protein molecules were not being recognized by the antibodies, or the glycation, and formation of crosslinks have blocked access of the antibodies to the antigen. It will conceal the effect of the linear dependence between the result (absorbance/densitometry) from the quantity of protein to which the antibody is directed. Springer US 2018-01-05 2018 /pmc/articles/PMC5849676/ /pubmed/29305778 http://dx.doi.org/10.1007/s10719-017-9805-4 Text en © The Author(s) 2018, corrected publication [January/2018] Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Kuzan, Aleksandra
Chwiłkowska, A.
Maksymowicz, K.
Bronowicka-Szydełko, A.
Stach, K.
Pezowicz, C.
Gamian, A.
Advanced glycation end products as a source of artifacts in immunoenzymatic methods
title Advanced glycation end products as a source of artifacts in immunoenzymatic methods
title_full Advanced glycation end products as a source of artifacts in immunoenzymatic methods
title_fullStr Advanced glycation end products as a source of artifacts in immunoenzymatic methods
title_full_unstemmed Advanced glycation end products as a source of artifacts in immunoenzymatic methods
title_short Advanced glycation end products as a source of artifacts in immunoenzymatic methods
title_sort advanced glycation end products as a source of artifacts in immunoenzymatic methods
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5849676/
https://www.ncbi.nlm.nih.gov/pubmed/29305778
http://dx.doi.org/10.1007/s10719-017-9805-4
work_keys_str_mv AT kuzanaleksandra advancedglycationendproductsasasourceofartifactsinimmunoenzymaticmethods
AT chwiłkowskaa advancedglycationendproductsasasourceofartifactsinimmunoenzymaticmethods
AT maksymowiczk advancedglycationendproductsasasourceofartifactsinimmunoenzymaticmethods
AT bronowickaszydełkoa advancedglycationendproductsasasourceofartifactsinimmunoenzymaticmethods
AT stachk advancedglycationendproductsasasourceofartifactsinimmunoenzymaticmethods
AT pezowiczc advancedglycationendproductsasasourceofartifactsinimmunoenzymaticmethods
AT gamiana advancedglycationendproductsasasourceofartifactsinimmunoenzymaticmethods